Urology Times staff

The toxicity profile was consistent with the first interim analysis of the phase 3 MAGNITUDE study with no new safety signals observed.

"These numbers compared favorably to [CheckMate-214], indicating the value of having a regimen where there was a defined treatment endpoint," says Michael B. Atkins, MD.

“We need to leverage these great platforms to put out high-quality information with experts that people can listen to from home or on the go and get the information that they need,” says Stacy Loeb, MD, MSc.

The updated data sustained the previous radiographic progression-free survival benefit observed with the niraparib combination and showed that the combination also met several secondary end points.

"[This is] a group of patients that there are few treatments available for, and we're excited about the data," says Daniel P. Petrylak, MD.

"Looking at the effect of the darolutamide on docetaxel, we didn't see much of a difference in dose reduction, dose modification, or dose hold for docetaxel, telling you that darolutamide didn't really affect the dosing of docetaxel," says Arash Rezazadah Kalebasty, MD.

"We're trying to understand where these new therapeutic agents might fit into our paradigms of care," says John L. Gore, MD, MS.

"This trial did not require a biomarker for entry in, so patients were treated with combination therapy or standard care, which would have been the abiraterone alone, to see if there was a benefit," says Michael S. Cookson, MD, MMHC.

“The effect size for adjuvant nivolumab versus placebo across primary, secondary, and exploratory endpoints is all remarkably stable,” says Matthew D. Galsky, MD.

"The median survival of the combination arm was 16.1 months versus 13.4 months in the standard chemo arm," says Enrique Grande, MD.

“There are a number of trials that we're interested in to develop potentially combining chemotherapy and neoadjuvant immunotherapy,” says Joshua J. Meeks, MD, PhD.

"The MMAI model had significantly improved accuracy and prognostication to discriminate which patients would develop distant metastasis or die from prostate cancer," says Daniel E. Spratt, MD.

“I would ask the practicing urologist to keep an open mind and not be dogmatic about how they've practiced in the past, and to consider the multiple lines of both indirect and direct evidence that exist,” says Surena F. Matin, MD.

"We found that if the patient has normal IsoPSA, he has only 1% of risk of developing clinically significant prostate cancer in a median follow-up time of 18 months," says Nour Abdallah, MD.

“Same-day discharge after partial nephrectomy in properly selected patients is safe and cost effective for both patients and the health system,” says Andrew Wood, MD.

“HIFU also has gone up in its APC, so there's a higher reimbursement for the facility fees for hospital or ASC setting,” says Jonathan Rubenstein, MD.

"The reason that we really focus on prostate cancer is because it's amenable to early screening. Early detection is key in cure," says Janet Kukreja, MD, MPH, FACS.

“Based off the questionnaire, [there was] statistically significant worsening quality of life, increased pain, and [increased] pain medicine requirement with a stent compared to without a stent,” says Christopher Allam, MD.

"This scope allowed me to maintain the intrarenal pressures lower than I would originally have done," says Naeem Bhojani, MD, FRCSC.

“I am seeing this process rapidly expand, particularly with the use of the single-port robot, which offers additional benefits to things like pain control and helps to further expedite early discharge,” Andrew Wood, MD.

“There are a couple of nomograms that are good for predicting either T2 or higher disease at time of surgery, so on final pathology, or T3 or higher,” says Suzanne Lange, MD.

"The biggest take-home message for any urologist who's treating kidney stones is to understand that what we consider to be success may not be what our patients consider to be success," says John Michael DiBianco, MD.

"Before you even start your contract negotiation, I think it's really important to have a negotiation with yourself and understand what's important to you," says Siobhan M. Hartigan, MD.

“I would just burn it into everyone's brain that pain with intercourse is also going to be associated with genitourinary syndrome of menopause,” says Rachel Pope, MD, MPH.

"It may be something that practicing urologists could already start speaking to their patients about," says Siobhan Sutcliffe, PhD, ScM, MHS.

"It wasn't just about the salary number, but what other things are within the contract that could make a huge difference on your practice and your life," says Siobhan M. Hartigan, MD.

“We highlighted that there is building evidence suggesting clinical benefits for lymph node dissection, such as a clear benefit of staging, which allows us to perform better prognostication for patients,” says Suzanne Lange, MD.

"This has the opportunity to really revolutionize the way we treat kidney stone disease via ureteroscopy," says Naeem Bhojani, MD.

"Major bladder reconstructive surgeries have the most room for improvement, particularly surgeries involving a bowel anastomosis; also our major oncologic surgeries—Wilm's tumor resections, those types of surgeries," says Sarah Hecht, MD.

“First and foremost is that same-day discharge appears to be safe. There were no failure-to-rescue events within 24 to 48 hours after discharge outside of the hospital,” says Andrew Wood, MD.